|
![]() |
Today's Health, Science, Technology, Personal Finance News(please report bugs and errors: suzanne@liveinfospace.com)
Both Child Safety Seats and Lap-and-Shoulder Seat Belts Effective in Preventing Serious Injury for ChildrenChicago, IL – September 4, 2008 – For young children, all states currently require the use of child safety seats, and the minimum age and weight requirements to graduate to seat belts has been increasing over time. A new study in the journal Economic Inquiry reveals that lap-and-shoulder seat belts perform as well as child safety seats in preventing serious injury. However, safety seats tend to be better at reducing less serious injuries. Steven D. Levitt of theUniversity of Chicago and author of the book Freakonomics and Joseph J. Doyle of the Massachusetts Institute of Technology analyzed three large representative samples of crashes reported to the police, as well as linked hospital data, among motor vehicle passengers aged 2-6 years of age. Researchers used the data to compare seat belts and child safety seats in preventing injury. Results show that lap-and-shoulder seat belts perform as well as child safety seats in preventing serious injury. Safety seats were associated with a statistically significant 25 percent reduction in less serious injuries. Lap belts are somewhat less effective than the other two types of restraints, but far superior to riding unrestrained. “Our comparisons across restraint types incorporate the way they are used, or misused, in practice,” the authors conclude. “Because many child safety seats are, in actual use, improperly installed, our estimates are likely to understate the benefits associated with their proper use. From a public policy perspective, however, understanding how safety devices work in practice, as opposed to under ideal circumstances, is of great importance.” _________________________________________________________________ This study is published in Economic Inquiry. Media wishing to receive a PDF of this article may contact journalnews@bos.blackwellpublishing.net. To view the abstract for this article, please click here. Steven D. Levitt is affiliated with the University of Chicago and can be reached for questions at slevitt@uchicago.edu. Published since 1962, (formerly Western Economic Journal), EI is widely regarded as one of the top scholarly journals in its field. Besides containing research on all economics topic areas, a principal objective is to make each article understandable to economists who are not necessarily specialists in the article's topic area. Nine Nobel laureates are among EI's long list of prestigious authors. Media ContactAmy MolnarPublicity Associate 111 River St. Hoboken, NJ 07030 USA 201-748-8844 (phone) 201-748-6088 (fax) amolnar@wiley.com Gene may hold key to neutralizing HIV - U.S. studyLast Updated: 2008-09-04 16:21:30 -0400 (Reuters Health) CHICAGO (Reuters) - The AIDS virus is especially hard to fight because few people develop antibodies to neutralize it, but U.S. researchers said on Thursday they have found an immunity gene that may offer a new way to fight back. They said the gene Apobec3 helps mice develop antibodies against an HIV-like virus, and they think the same gene in humans could lead to a potent vaccine against the human immunodeficiency virus or HIV. "This gene is central to HIV biology," Dr. Warner Greene of the Gladstone Institutes at the University of California, San Francisco, said in a telephone interview. So far, efforts to make a vaccine against HIV have failed. In humans, HIV devotes one of its 9 genes to disabling Apobec3 proteins, which may help explain why people with HIV rarely make antibodies against the virus, he said. HIV is a retrovirus, which means it copies bits of its own genetic code into the DNA of the host. "If we could prevent HIV from destroying this key pivotal host factor, we might allow HIV-infected patients to develop neutralizing antibodies like they do in mice," he said. "It's a translation from mice to men. That's the challenge now," said Greene, whose study appears in the journal Science. Green's lab and others have been hunting for the gene in mice that allows them to fight off the Friend virus, a retrovirus similar to HIV. Working with a team at the National Institute of Allergy and Infectious Diseases, the researchers conducted a series of experiments in which they genetically engineered mice to lack the Apobec3 gene. "Sure enough, when we knocked out the Apobec3 gene, they lost their ability to recover from Friend virus infection," Greene said. He said the discovery of Apobec3's role in retroviral immunity is exciting because genes in this region are active in people who resist HIV infection, suggesting they are making effective antibodies against the virus. "Blocking this degradation of Apobec3 is probably the most promising new drug target in HIV biology," Greene said. Antibodies are key to warding off viral infections, and most vaccines against viral diseases stimulate the body to make antibodies against the target virus. Greene said efforts at developing an HIV vaccine have largely focused on building up a kind of immune cell called a T-cell to attack the virus. "Those types of approaches are not proving adequate. We are desperately seeking better approaches to creating neutralizing antibodies," he said, adding, "Maybe this will help us." The AIDS virus infects an estimated 33 million people globally and has killed about 25 million since the pandemic started in the 1980s. There is no cure but drugs can suppress the virus and allow patients to lead a near-normal life. Without treatment, the virus destroys the immune system, leaving patients susceptible to infections and cancer. Copyright © 2008 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world. Mood in pregnancy impacts early child developmentLast Updated: 2008-09-04 11:00:59 -0400 (Reuters Health) NEW YORK (Reuters Health) - Some of the harmful effects on early child development attributed to postpartum depression may be caused in part by depression during pregnancy, a UK study shows for the first time. Maternal depression during pregnancy "has a negative impact on children's cognitive development, even when postnatal (after delivery) depression has been taken into account," Dr. Toity Deave told Reuters Health. "It is widely acknowledged that postnatal depression has a negative impact on child development but this is the first study that has demonstrated that the children of women who experience low mood during pregnancy are also at risk," said Deave, from the Centre for Child and Adolescent Health, University of the West of England, Bristol. The findings come from a long-term study of 9,244 women and their children. A total of 1,565 women, or 14 percent, suffered from depression while pregnant but not after 2 months following delivery, Dave and colleagues report in the medical journal BJOG. Standard developmental screening tests in the children showed that 893, or 9 percent, were developmentally delayed at age 18 months. A developmental delay is any significant lag in a child's physical, cognitive, behavioral, emotional, or social development, in comparison with established normal ranges for his or her age. Deave and colleagues found that persistent depression in the mother during pregnancy increased the odds of developmental delay in the son or daughter by 50 percent. After factoring in the effects of depression early after delivery, the researchers say they found evidence of an "independent and statistically significant" 34 percent increase in the odds of developmental delay in children of mothers who were depressed while pregnant. This study, they say, adds to "increasing evidence that the mother's mood during pregnancy is important" and that any persistent depression during pregnancy has the potential to raise the risk for developmental delay in childhood. "For the women who might be worried reading this, I would recommend that, if they do feel depressed or experience a low mood that is unusual for them, they go and see a health professional," Deave suggested. "I would like to reassure parents," Deave added, "that there is a lot that they themselves can do to promote their child's development even if there is depression in the family. This can be through close parent-child interactions and, for example, stimulating and fun play." SOURCE: BJOG: An International Journal of Obstetrics and Gynaecology, July 2008. Copyright © 2008 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world. Eating More Protein In The Morning Helps Dieters Retain Fullness Throughout The DayA new study published online in the British Journal of Nutrition found that timing of dietary protein intake affects feelings of fullness throughout the day. The study concluded that when people ate high-quality protein foods, from sources such as eggs and lean Canadian bacon, for breakfast they had a greater sense of sustained fullness throughout the day compared to when more protein was eaten at lunch or dinner.i"There is a growing body of research which supports eating high-quality protein foods when dieting to maintain a sense of fullness," said Wayne W. Campbell, PhD, study author and professor of Foods and Nutrition at Purdue University. "This study is particularly unique in that it looked at the timing of protein intake and reveals that when you consume more protein may be a critical piece of the equation." A Closer Look at the Study The study included overweight or obese men who ate a reduced calorie diet. The diet consisted of two variations of protein intakes, both which were within federal nutrition recommendations: normal protein intake (11-14 percent of calories) or increased protein (18-25 percent of calories). The researchers tested the effect of consuming the additional protein at specific meals - breakfast, lunch or dinner - or spaced evenly throughout the day. Purdue researchers found that the feeling of fullness was greatest and most sustained throughout the day when the additional protein, from eggs and lean Canadian bacon, was eaten at breakfast - versus lunch or dinner. Additional Research This study adds to a growing body of research on the benefits of eating high-quality protein for weight management. Recent research provides further evidence to support the findings of this study:
The authors of the British Journal of Nutrition study note that most Americans typically consume a relatively small amount of protein at breakfast - only about 15 percent of their total daily protein intake. Additionally, consumer research by the International Food Information Council shows that 92 percent of Americans cite breakfast as the most important meal of the day, however less than half (46 percent) eat breakfast seven days per week.iv "It strikes me that there is a real opportunity to increase protein intake at breakfast to see a meaningful impact on people's weight loss efforts," said Keith Ayoob, EdD, RD, FADA, a nutritionist and associate professor of pediatrics at the Albert Einstein College of Medicine. "Many people are caught in a boring breakfast rut, or say they simply don't have enough time to eat in the morning, but with a little planning, breakfast can easily be one of the most fulfilling meals of the day." Ayoob provides the following tips for easy, high-quality protein based breakfasts:
About the American Egg Board (AEB) AEB is the U.S. egg producer's link to the consumer in communicating the value of The incredible edible egg™ and is funded from a national legislative checkoff on all egg production from companies with greater than 75,000 layers, in the continental United States. The board consists of 18 members and 18 alternates from all regions of the country who are appointed by the Secretary of Agriculture. The AEB staff carries out the programs under the board direction. AEB is located in Park Ridge, Ill. Visit http://www.incredibleegg.org/ for more information. About the Egg Nutrition Center (ENC) The Egg Nutrition Center (ENC) is the health education and research center of the American Egg Board. Established in 1979, ENC provides science-based information to health promotion agencies, physicians, dietitians, nutritional scientists, media and consumers on issues related to egg nutrition and the role of eggs in the American diet. ENC is located in Washington, DC. Visit http://www.enc-online.org/ for more information. About the National Pork Board The National Pork Board has responsibility for Checkoff-funded research, promotion and consumer information projects and for communicating with pork producers and the public. Through a legislative national Pork Checkoff, pork producers invest $0.40 for each $100 value of hogs sold. The Pork Checkoff funds national and state programs in nutrition research, promotion, consumer information, export market promotion, production improvement, technology, swine health, pork safety and environmental management. Visit http://www.theotherwhitemeat.com/ for more information.
The Egg Nutrition News Bureau What A Sleep Study Can Reveal About FibromyalgiaResearch engineers and sleep medicine specialists from two Michigan universities have joined technical and clinical hands to put innovative quantitative analysis, signal-processing technology and computer algorithms to work in the sleep lab. One of their recent findings is that a new approach to analyzing sleep fragmentation appears to distinguish fibromyalgia patients from healthy controls.httJoseph W. Burns, a research scientist and engineer at the Michigan Tech Research Institute (MTRI); Ronald D. Chervin, director of the University of Michigan's Michael S. Aldrich Sleep Disorders Laboratory; and Leslie Crofford, director of the Center for the Advancement of Women's Health at the University of Kentucky, report the results of their study in the current issue of the journal Sleep Medicine MTRI, a freestanding research institute acquired by Michigan Tech in 2006 and based in Ann Arbor, specializes in remote sensors that collect data, and in signal processing, using algorithms or computer programs to analyze and correlate the information the sensors gather. MTRI has developed an ongoing collaboration with the University of Michigan's sleep laboratory, one of the nation's leading clinical and research centers specializing in sleep medicine. This several-year collaboration provided MTRI's first opportunities to apply quantitative analysis, remote sensing technology and computer algorithms to clinical challenges, said Burns. "In this case, our analyses of sleep stage dynamics suggest potential clinical relevance," he noted. Newly explored measures of sleep fragmentation seem to correlate - at least in this study - with levels of pain reported by fibromyalgia patients. Burns, who has a PhD in electrical engineering, finds that more and more of his research is taking a biomedical turn. He and his team are working with Chervin to use signal-processing technology to record and analyze the brain waves and biophysical responses of children and adults with a variety of sleep disorders. They hope it will help them better understand conventional sleep patterns, as well as diagnose and treat sleep disorders. They presented the results of research related to assessment of sleep-disordered breathing and sleep fragmentation at Sleep 2008, an international sleep research conference, in Baltimore in June. Patients who may have sleep disorders often undergo complicated and expensive tests in sleep laboratories, Chervin explained. These studies collect an assortment of biophysical data that reflect brain, cardiovascular and muscle activity throughout the night. Up to now, these data had to be analyzed manually by highly trained technicians. "We are collaborating to find new ways to analyze routinely collected data in a way that will be meaningful to the patient's health and will help us understand how sleep disorders affect brain functions," he said. Automated analysis of data potentially can provide improved assessments and reduce the cost of sleep studies, Burns noted. For example, MTRI and UM have developed an automated technique for assessing the severity of sleep-disordered breathing, using just two signals - brain waves and respiration - instead of the dozen or more signals typically needed for standard visual scoring of a sleep study. "It may even become possible for people to take sleep tests - simpler and more effective than some of those currently available - at home where they can sleep in their own familiar bedrooms," he suggested. Both partners are reaping the benefits of the collaboration, Burns said. Not only can automated technology improve clinical research; what the MTRI scientists have learned about biomedical techniques such as brain mapping is informing their more traditional work on radar and optical sensing technology. Michigan Tech and UM have patented the new algorithm for assessing sleep-disordered breathing, which enables them to study what the extra work of breathing does to the brainwaves of patients with sleep apnea, a sleep disorder in which breathing stops briefly many times during sleep. Sleep apnea has been linked to excessive daytime sleepiness, cognitive changes and other health effects, and to hyperactive behavior in children. The universities have filed an application for another patent for an algorithm that helps automate the assessment of patients with REM Sleep Behavior Disorder. People with this neurological condition act out their dreams during Rapid Eye Movement (REM) sleep, which can cause them to harm themselves or a bed partner while they are asleep. Burns and Chervin published the results of that study in the December 2007 issue of the journal Sleep. The team plans to investigate other sleep disorders and to continue to develop automated processing techniques to improve the performance and efficiency of sleep disorder diagnosis and assessment. Michigan Technological University is a leading public research university, conducting research, developing new technologies and preparing students to create the future for a prosperous and sustainable world. Michigan Tech offers more than 120 undergraduate and graduate degree programs in engineering, forestry and environmental sciences, computing, technology, business and economics, natural and physical sciences, arts, humanities and social sciences. Internationally renowned for patient care, research and education, the University of Michigan Health System has been a leader in American medicine for more than a century and a half. UMHS includes the U-M Medical School, three nationally ranked hospitals, 40 outpatient health centers, and a number of specialized programs for treatment and research in cancer, cardiovascular disease, geriatrics, depression, diabetes, vision, women's health, organ transplant and other specialties. Its biomedical research community is one of the nation's largest, winning more than $342 million in funding each year while generating more than 120 newly disclosed inventions annually. ---------------------------- Article adapted by Medical News Today from original press release. ---------------------------- Source: Jennifer Donovan Michigan Technological University Blood 'Fingerprints' For CancerSerum microRNAs (miRNAs) can serve as biomarkers for the detection of diseases including cancer and diabetes, according to research published online this week in Cell Research. The findings pave the way for a revolutionary non-invasive diagnostic tool.miRNAs are a class of naturally occurring small non-coding RNAs that have been linked with cancer development. Recent studies reporting individual miRNAs as diagnostic biomarkers of specific cancers were unable to rule out the possibility that these miRNAs appeared as a result of contamination. Chen-Yu Zhang and colleagues are the first to comprehensively characterize entire blood miRNA profiles of healthy subjects and patients with lung cancer, colorectal cancer and diabetes, ruling out contamination. They propose that the specific serum miRNA expression profiles they identified constitute 'fingerprints' for cancer and disease. Although tumour markers greatly improve diagnosis, current diagnostic techniques are prohibitively invasive and therefore have limited clinical application. The new approach is non-invasive and has the potential to transform the clinical management of various cancers and diseases through improving disease diagnosis, cancer classification, prognosis estimation, prediction of therapeutic efficacy, maintenance of surveillance following surgery, and the ability to forecast disease recurrence. The new technique will also be useful to pharmacological companies in identifying population subgroups who are responsive to drugs that have failed in phase III clinical trials. Author: Chen-Yu Zhang (Nanjing University, Jiangsu, China) Editorial: Dangsheng Li (Cell Research, Shanghai, China) Source: Chen-Yu Zhang Nanjing University School of Life Sciences New Device Helps Premature Babies Suck Better, Faster -- And That's GoodAs if things weren't tough enough for premature babies who have tubes down their
throats and noses to survive, once the tubes are removed, they are often unable
to take nourishment orally that is, suck. Unlocked: The genetic secrets behind pancreatic and brain cancer that could open door to new treatmentsBy David Derbyshire The genetic secrets of two of the most deadly cancers have been unlocked by scientists in a breakthrough that paves the way for a host of new treatments. In the biggest study of its kind, researchers have found dozens of broken, missing and overactive genes that trigger the growth of potentially lethal tumours of the brain and pancreas. The results help to explain why the cancers are so hard to treat with conventional drugs. They also open the door to new tests and drugs to stop the diseases in their early stages. Cancers arise from changes that accumulate in cells' DNA over the course of someone's life. The changes can eventually lead to a cell's uncontrolled growth. The new study - which involved researchers from 18 universities and institutions - decoded the DNA of brain and pancreas tumour cells taken from more than 40 patients. The findings suggest that a conventional war on cancer is unlikely to succeed, according to US expert Prof Kenneth Kinzler, one of the researchers involved. 'The landscape of human cancers is clearly more complex than has been previously appreciated,' said Prof Kinzler, from Johns Hopkins Medical Institutions in Baltimore, Maryland. 'Fighting it is going to be more of a guerilla war than a conventional one
because there are dozens of mutated genes in each tumour. Individually, these
mutations don't seem formidable. 'But working together, they form an enemy that will require us to develop novel strategies to combat them, and the best long-term strategy may be early detection of tumours, when the number of guerilla warriors is still small and more easily handled.'
Deadly: Around 4,500 brain tumours are diagnosed each year in the UK and most people die within 14 months of diagnosis Two teams looked at pancreatic cancer and the most common and dangerous form
of brain cancer, glioblastoma multiforme (GBM). Their results were published today in online versions of the journals Science and Nature. One team of scientists - which included Prof Kinzler - analysed the DNA of more than 20,000 genes from 24 pancreatic and 22 brain tumours. They found around a dozen chemical pathways in cells which contribute to the development and growth of the cancer. They also found 83 gene mutations involved in pancreatic cancer and 42 in glioblastoma. Members of the second team, focused on brain cancer and analysed 623 genes from 91 tumours. They identified some genes known to cause cancer but whose role had previously been underestimated along with genes not previously known to contribute to the disease. Co-author Dr David Wheeler, Washington University School of Medicine in St Louis, Missouri, US, said: 'Studies like this show the breadth of mutation across many genes. We can see the mutations in all the genes of each pathway that control growth, replication and death in the cancer cell. 'Researchers have never seen the whole landscape like this before, and it's
providing many new insights into strategies to diagnose and treat cancer.' Pancreatic cancer is the 10th most common cancer in Britain and mostly affects people in middle and old age. Around 7,400 people are diagnosed with the disease each year - usually too late for effective treatment, meaning most people are given a diagnosis of less than a year to live. The actor Patrick Swayze was diagnosed with the condition earlier this year. Around 4,500 brain tumours are diagnosed each year in the UK. Glioblastoma is the most common and aggressive variety. The cancer grows quickly and most people die within 14 months of diagnosis.
Major News Of The Day9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008 9/5/2008
|